Ellen Feigal

Director/Board Member at XENCOR, INC.

Net worth: 307 883 $ as of 29/09/2026

71 year

89 connections

Consumer Services

Health Technology

Commercial Services

Profile

Dr. Ellen G.
Feigal, MD, is an Independent Director at NextCure, Inc., an Independent Director at Xencor, Inc. and a Partner & Head-Biologics Practice at NDA Partners LLC.
She is on the Board of Directors at Prescient Therapeutics Ltd., NextCure, Inc., Xencor, Inc. and Foundation For Cell & Gene Medicine.
Dr. Feigal was previously employed as a Vice President-Research & Development by California Institute for Regenerative Medicine, an Executive Medical Director-Global Development by Amgen, Inc., a Chief Medical Officer by INSYS Therapeutics, Inc., a Director-Medical Devices & Imaging by Critical Path Institute, a Director-American Course on Drug Development by University of California, a Vice President-Clinical Sciences by Translational Genomics Research Institute, and a Deputy Director-Cancer Treatment Division by National Cancer Institute.
She also served on the board at The University of California, San Francisco.
She received her undergraduate degree from the University of Minnesota, a graduate degree from the University of California, Berkeley, a doctorate degree from the University of California, Davis and a doctorate degree from Stanford University School of Medicine.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
XENCOR, INC. 0.02%	17/06/2026	12,340 ( 0.02% )	307 883 $	29/09/2026
NEXTCURE, INC. -.--%	17/06/2026	0 ( -.--% )	- $	29/09/2026
PRESCIENT THERAPEUTICS LIMITED -.--%	29/06/2025	0 ( -.--% )	- $	29/09/2026

Ellen Feigal active positions

Companies	Position	Start
NEXTCURE, INC.	Director/Board Member	30/09/2021
PRESCIENT THERAPEUTICS LIMITED	Director/Board Member	14/05/2023
XENCOR, INC.	Director/Board Member	31/10/2018
NDA Partners LLC NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services	Corporate Officer/Principal	30/11/2014
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine.	Director/Board Member	-

All active positions of Ellen Feigal

Former positions of Ellen Feigal

Companies	Position	End
California Institute for Regenerative Medicine California Institute for Regenerative Medicine General GovernmentGovernment Provides medical services	Chief Tech/Sci/R&D Officer	30/11/2014
University of California University of California Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	31/12/2010
AMGEN INC.	Corporate Officer/Principal	31/12/2010
INSYS THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	31/12/2007
░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░

See the detail of Ellen Feigal's experience

Education of Ellen Feigal

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ellen Feigal's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	17
Amgen, Inc. Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics	Health Technology
Xencor, Inc. Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions	Health Technology
Prescient Therapeutics Ltd. Prescient Therapeutics Ltd. BiotechnologyHealth Technology Operates as a a clinical stage oncology company	Health Technology
University of California, Berkeley University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of California, Davis University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Minnesota University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The University of California, San Francisco The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
National Cancer Institute National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research	Miscellaneous
California Institute for Regenerative Medicine California Institute for Regenerative Medicine General GovernmentGovernment Provides medical services	Government
NDA Partners LLC NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services	Commercial Services
Translational Genomics Research Institute Translational Genomics Research Institute Miscellaneous Commercial ServicesCommercial Services Operates as a cancer, neurological disorders and infectious disease medical research institute	Commercial Services
Critical Path Institute Critical Path Institute Miscellaneous Commercial ServicesCommercial Services Provides medical drug and product development review process	Commercial Services
INSYS Therapeutics, Inc. INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a specialty pharmaceutical company	Health Technology
University of California University of California Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Stanford University School of Medicine Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
NextCure, Inc. NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases	Health Technology
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine.